These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 23486191)

  • 1. Effect of long-term intensive lipid-lowering therapy with rosuvastatin on progression of carotid intima-media thickness--Justification for Atherosclerosis Regression Treatment (JART) extension study.
    Nohara R; Daida H; Hata M; Kaku K; Kawamori R; Kishimoto J; Kurabayashi M; Masuda I; Sakuma I; Yamazaki T; Yokoi H; Yoshida M;
    Circ J; 2013; 77(6):1526-33. PubMed ID: 23486191
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Change in carotid intima-media thickness in a high-risk group of patients by intensive lipid-lowering therapy with rosuvastatin: subanalysis of the JART study.
    Yokoi H; Nohara R; Daida H; Hata M; Kaku K; Kawamori R; Kishimoto J; Kurabayashi M; Masuda I; Sakuma I; Yamazaki T; Yoshida M
    Int Heart J; 2014; 55(2):146-52. PubMed ID: 24632963
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Can intensive lipid-lowering therapy improve the carotid intima-media thickness in Japanese subjects under primary prevention for cardiovascular disease?: The JART and JART extension subanalysis.
    Daida H; Nohara R; Hata M; Kaku K; Kawamori R; Kishimoto J; Kurabayashi M; Masuda I; Sakuma I; Yamazaki T; Yokoi H; Yoshida M;
    J Atheroscler Thromb; 2014; 21(7):739-54. PubMed ID: 24953046
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of intensive lipid-lowering therapy with rosuvastatin on progression of carotid intima-media thickness in Japanese patients: Justification for Atherosclerosis Regression Treatment (JART) study.
    Nohara R; Daida H; Hata M; Kaku K; Kawamori R; Kishimoto J; Kurabayashi M; Masuda I; Sakuma I; Yamazaki T; Yokoi H; Yoshida M;
    Circ J; 2012; 76(1):221-9. PubMed ID: 22094911
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of rosuvastatin on serum lipids and arteriosclerosis in dyslipidemic patients with cerebral infarction.
    Deguchi I; Horiuchi Y; Hayashi T; Sehara Y; Kato Y; Ohe Y; Fukuoka T; Maruyama H; Sano H; Nagamine Y; Tanahashi N
    J Stroke Cerebrovasc Dis; 2014 Sep; 23(8):2007-2011. PubMed ID: 25066602
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Two-year treatment with rosuvastatin reduces carotid intima-media thickness in HIV type 1-infected patients receiving highly active antiretroviral therapy with asymptomatic atherosclerosis and moderate cardiovascular risk.
    Calza L; Manfredi R; Colangeli V; Trapani FF; Salvadori C; Magistrelli E; Danese I; Verucchi G; Serra C; Viale P
    AIDS Res Hum Retroviruses; 2013 Mar; 29(3):547-56. PubMed ID: 23098891
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevention of atherosclerosis in patients living with HIV.
    De Lorenzo F; Boffito M; Collot-Teixeira S; Gazzard B; McGregor JL; Shotliff K; Xiao H
    Vasc Health Risk Manag; 2009; 5(1):287-300. PubMed ID: 19436663
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of 2-year treatment with low-dose rosuvastatin on intima-media thickness in hypercholesterolemic subjects with asymptomatic carotid artery disease.
    Riccioni G; Cipollone F; Santovito D; Scotti L; D'Orazio N; Mezzetti A; Bucciarelli T
    Expert Opin Pharmacother; 2011 Dec; 12(17):2599-604. PubMed ID: 21999752
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intensive lipid-lowering therapy for slowing progression as well as inducing regression of atherosclerosis in Japanese patients: subanalysis of the JART study.
    Yamazaki T; Nohara R; Daida H; Hata M; Kaku K; Kawamori R; Kishimoto J; Kurabayashi M; Masuda I; Sakuma I; Yokoi H; Yoshida M;
    Int Heart J; 2013; 54(1):33-9. PubMed ID: 23428922
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial.
    Crouse JR; Raichlen JS; Riley WA; Evans GW; Palmer MK; O'Leary DH; Grobbee DE; Bots ML;
    JAMA; 2007 Mar; 297(12):1344-53. PubMed ID: 17384434
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Can intensive lipid-lowering therapy with statins ameliorate atherosclerosis in Japanese patients? Rationale and design of the JART study.
    Kurabayashi M; Sakuma I; Kawamori R; Daida H; Yamazaki T; Yoshida M; Hata M; Masuda I; Kaku K; Yokoi H; Kishimoto J; Nohara R
    J Atheroscler Thromb; 2010 Apr; 17(4):416-22. PubMed ID: 20215710
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low-dose rosuvastatin improves the functional and morphological markers of atherosclerosis in asymptomatic postmenopausal women with dyslipidemia.
    Igase M; Kohara K; Tabara Y; Nagai T; Ochi N; Kido T; Ochi M; Miki T
    Menopause; 2012 Dec; 19(12):1294-9. PubMed ID: 22850442
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of effects of rosuvastatin and atorvastatin on plaque regression in Korean patients with untreated intermediate coronary stenosis.
    Hong YJ; Jeong MH; Hachinohe D; Ahmed K; Choi YH; Cho SH; Hwang SH; Ko JS; Lee MG; Park KH; Sim DS; Yoon NS; Yoon HJ; Kim KH; Park HW; Kim JH; Ahn Y; Cho JG; Park JC; Kang JC
    Circ J; 2011; 75(2):398-406. PubMed ID: 21157106
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of rosuvastatin on subclinical atherosclerosis and arterial stiffness in rheumatoid arthritis: a randomized controlled pilot trial.
    Tam LS; Li EK; Shang Q; Tomlinson B; Lee VW; Lee KK; Li M; Kuan WP; Li TK; Tseung L; Yip GW; Freedman B; Yu CM
    Scand J Rheumatol; 2011 Nov; 40(6):411-21. PubMed ID: 21867445
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rosuvastatin: a review of its effect on atherosclerosis.
    Keating GM; Robinson DM
    Am J Cardiovasc Drugs; 2008; 8(2):127-46. PubMed ID: 18422395
    [TBL] [Abstract][Full Text] [Related]  

  • 16. One-year treatment with rosuvastatin reduces intima-media thickness in 45 hypercholesterolemic subjects with asymptomatic carotid artery disease.
    Riccioni G; Vitulano N; Mancini B; Zanasi A; D'Orazio N
    Pharmacology; 2010; 85(2):63-7. PubMed ID: 20110750
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rosuvastatin-Induced Carotid Plaque Regression in Patients With Inflammatory Joint Diseases: The Rosuvastatin in Rheumatoid Arthritis, Ankylosing Spondylitis and Other Inflammatory Joint Diseases Study.
    Rollefstad S; Ikdahl E; Hisdal J; Olsen IC; Holme I; Hammer HB; Smerud KT; Kitas GD; Pedersen TR; Kvien TK; Semb AG
    Arthritis Rheumatol; 2015 Jul; 67(7):1718-28. PubMed ID: 25778850
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intensive lipid lowering may reduce progression of carotid atherosclerosis within 12 months of treatment: the METEOR study.
    Bots ML; Palmer MK; Dogan S; Plantinga Y; Raichlen JS; Evans GW; O'Leary DH; Grobbee DE; Crouse JR;
    J Intern Med; 2009 Jun; 265(6):698-707. PubMed ID: 19298496
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Daily and intermittent rosuvastatin 5 mg therapy in statin intolerant patients: an observational study.
    Meek C; Wierzbicki AS; Jewkes C; Twomey PJ; Crook MA; Jones A; Viljoen A
    Curr Med Res Opin; 2012 Mar; 28(3):371-8. PubMed ID: 22256801
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of rosuvastatin on ROCK activity, endothelial function, and inflammation in Asian patients with atherosclerosis.
    Liu B; Zhang JY; Cao HM; Wang Q; Wang HB
    Intern Med; 2012; 51(10):1177-82. PubMed ID: 22687786
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.